{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["Liver metastases from colorectal cancer","Cancer-Bowel-Back passage (rectum) or large bowel (colon)","Cancer-Liver"],"disease":["Liver Metastases From Colorectal Cancer","Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)","Cancer-liver"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2452750"],"location":["New Zealand","Belgium","United States","Australia","Germany","Spain"],"study_start_month":["4"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"SIRFLOX Study","description":"Interventions: The study intervention will consist of FOLFOX6m chemotherapy plus a single implantation of selective internal radiation therapy in the form of SIR-Spheres microspheres administered on the 3rd day of the first cycle of chemotherapy. The chemotherapy will be administered until treatment failure (as assessed by progression of disease) or until chemotherapy toxicity is reported. \nBased on preliminary data it is thought that time to progression of disease in the treatment group could be 11 months or more.\nPrimary outcome(s): Progression free survival at any site[Progression to be assessed by CT scan every 2 months.]\nStudy Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Efficacy","dates":{"creation":"2006-04-15"},"accession":"2452750","cross_references":{"Australian New Zealand Clinical Trials Registry":["ACTRN12606000153516"]}}